Promise and Limits of the CellSearch® Platform for Evaluating Pharmacodynamics in Circulating Tumor Cells (CTC)

We present representative data from three clinical trials with the PARP inhibitor veliparib (ABT-888) suggesting that CTCs can be used to measure PD effects, but our experience points to the difficulty in obtaining sufficient EpCAM-expressing CTCs from patients with advanced disease to reach statistically significant conclusions about PD effects from each trial, instead often leading to hypothesis generating information.
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Source Type: research